Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer

George, Thomashire A.; Chen, Max M.; Czosseck, Andreas; Chen, Hsiang-Pei; Huang, Hsu-Shan; Lundy, David J.

doi:10.1016/j.jconrel.2021.12.001

Cited by 11 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid nanocarriers have been extensively studied and are clinically used in applications such as cancer. They are also promising candidates for drug delivery to the infarcted heart [ 22 , 75 ]. Their circulatory properties can also be modified by conjugating the surface with PEG, which helps to prevent phagocytic clearance and prolong circulation time, thus increasing their capacity for passive targeting.…”

Section: Nanomedicines For Cardiac Therapymentioning

confidence: 99%

Nanocarrier-Based Targeted Therapies for Myocardial Infarction

et al. 2022

Self Cite

View full text Add to dashboard Cite

Myocardial infarction is a major cause of morbidity and mortality worldwide. Due to poor inherent regeneration of the adult mammalian myocardium and challenges with effective drug delivery, there has been little progress in regenerative therapies. Nanocarriers, including liposomes, nanoparticles, and exosomes, offer many potential advantages for the therapy of myocardial infarction, including improved delivery, retention, and prolonged activity of therapeutics. However, there are many challenges that have prevented the widespread clinical use of these technologies. This review aims to summarize significant principles and developments in the field, with a focus on nanocarriers using ligand-based or cell mimicry-based targeting. Lastly, a discussion of limitations and potential future direction is provided.

show abstract

Section: Nanomedicines For Cardiac Therapymentioning

confidence: 99%

Nanocarrier-Based Targeted Therapies for Myocardial Infarction

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The silicone pad (2) contains channel (c) that conducts the suspension from the inlet downwards the polycarbonate filter membrane (m) (d = 19 mm; pore size 100 nm) was held by the silicone pad (3). The central PMMA sheet (4) acts as the filter support which has a central circular area (d = 0.6 mm) with multiple small holes and is attached to a silicone pad (5). On the bottom, PMMA sheet (6) contains channels (c) that collect and guide the filtered suspension to the outlet port.…”

Section: Liposome Extruder Fabricationmentioning

confidence: 99%

“…anthraquinone, ursolic acid and phenolic compounds) have been encapsulated into liposome and exhibited enhanced anti-tumor activities. [3][4][5][6][7][8] The efficacy against various types of cancer of liposomal delivery systems have been significantly extended by the synergistic effects resulted from their combinations with other drugs (i.e. combination therapy), physical agents (i.e.…”

Section: Introductionmentioning

confidence: 99%

A low-cost, flexible extruder for liposomes synthesis and application for Murrayafoline A delivery for cancer treatment

et al. 2022

View full text Add to dashboard Cite

Liposomal encapsulation is a drug delivery strategy with many advantages, such as improved bioavailability, ability to carry large drug loads, as well as controllability and specificity towards various targeted diseased tissues. Currently, most preparation techniques require an additional extrusion or filtering step to obtain monodisperse liposomes with the size of less than 100 nm. In this study, a compact liposome extruder was designed at a cost of $4.00 and used to synthesize liposome suspensions with defined particle size and high homogeneity for Murrayafoline A (Mu-A) loading and release. The synthesized MuA-loaded liposomes displayed a biphasic drug release and remained stable under the storage condition of 4°C. They also significantly reduced the viability of HepG2 cells in the cancer spheroids by 25%. The low-cost, flexible liposome extruder would allow the researchers to study liposomes and their applications in a cost-effective manner.

show abstract

“…[33] NP-based drugs are actively researched and developed for treatment of various types of cancer. Some of these drugs have already been approved by the FDA for use in patients (e.g., Abraxane, Doxil, Oncaspar, and Nanotherm [33] ), while others are still in clinical trials, for example, liposomes encapsulating small molecules for liver cancer [34] or micellar nanocarriers for gemcitabine/erlotinib co-delivery (pancreatic cancer). [35] The arginine-glycine-glutamic acid (RGD) sequence is an 𝛼v𝛽3 integrin (an endothelial cell receptor) recognition site.…”

Section: Introductionmentioning

confidence: 99%

Tumor‐Targeted Poly(ArgGlyAsp) Nanocapsules for Personalized Cancer Therapy – In Vivo Study

Itzhaki

Chausky‐Barzakh

Atkins

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

The arginine‐glycine‐glutamic acid (RGD) sequence, an αvβ3 integrin recognition site, is overexpressed in malignancies and neovasculature, making it a potential therapeutic target. Herein, efficacy/safety of tumor‐targeted RGD‐based proteinoid nanocapsules (NCs) entrapping a synergistic combination of two drugs—palbociclib (Pal), a CDK4/6 inhibitor, and alpelisib (Alp), a P13K inhibitor, as a cancer treatment, is assessed. P(RGD) proteinoid polymers are produced by thermal step‐growth polymerization of R, G, and D under an inert atmosphere. P(RGD) NCs, hollow and encapsulating 25 w% each of Pal and Alp, are formed by self‐assembly of the proteinoid polymer. The encapsulation yields of Pal and Alp are 72% and 95%, respectively. Long‐term stability, controlled release, cellular uptake,synergistic cytotoxicity, and induced cell death are evident from in vitro experiments. Findings from in vivo breast, colon and gastric patient‐derived xenograft (PDX) mice experiments are consistent with the in vitro studies showing that the response to treatment with drug‐loaded NCs is similar to that elicited by free drugs, with reduced side effects. The study demonstrates the potential clinical utility of P(RGD) NCs for cancer treatment.

show abstract

Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer

Cited by 11 publications

References 54 publications

Nanocarrier-Based Targeted Therapies for Myocardial Infarction

Nanocarrier-Based Targeted Therapies for Myocardial Infarction

A low-cost, flexible extruder for liposomes synthesis and application for Murrayafoline A delivery for cancer treatment

Tumor‐Targeted Poly(ArgGlyAsp) Nanocapsules for Personalized Cancer Therapy – In Vivo Study

Contact Info

Product

Resources

About